Recombinant Expression Vectors for Scalable SARS-CoV-2 Antibody Production

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is an urgent need for large-scale production of recombinant vectors that deliver highly potent neutralizing antibodies against SARS-CoV-2, as convalescent plasma treatment is limited by its reliance on donations from recovered individuals and cannot be scaled up.

Innovation Solution

Development of recombinant expression vectors that encode anti-SARS-CoV-2 neutralizing antibodies or antigen-binding fragments, specifically utilizing nucleic acid sequences for heavy and light chain complementarity-determining regions (CDRs) and variable regions, integrated into expression cassettes within viral vectors like lentivirus or adeno-associated virus (AAV) for efficient production and distribution.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If convalescent plasma treatment is used to treat COVID-19 patients, then neutralizing antibodies are provided to combat the virus, but the treatment cannot be produced on a large scale due to reliance on donations from recovered individuals

Engineering Contradiction:

Improvesupply of neutralizing antibodiesVSAvoidscalability of production

Core Design Contradiction:

Quantity of substanceVSEase of manufacture

Solution Approach 1:

The patent creates recombinant copies of neutralizing antibodies through genetic engineering. The antibody-encoding genes are inserted into expression vectors that can be replicated and expressed in host cells, producing large quantities of identical antibody molecules without relying on plasma donations from recovered patients

Inventive Principle:

Principle #26Copying

Solution Approach 2:

The patent establishes self-sustaining production systems where host cells (bacterial, insect, or mammalian cells) are transformed with expression vectors and can autonomously produce the neutralizing antibodies. The cells serve as living factories that continuously generate the therapeutic antibody through their own cellular machinery

Inventive Principle:

Principle #25Self-service

2Productivity

If recombinant expression vectors are developed to produce neutralizing antibodies on a large scale, then the supply and scalability are improved, but the complexity of the production system increases

Engineering Contradiction:

Improveproduction capacity of neutralizing antibodiesVSAvoidcomplexity of expression vector system

Core Design Contradiction:

ProductivityVSDevice complexity

Solution Approach 1:

The patent divides the complex production system into modular components: expression vectors containing antibody-encoding genes, host cells for expression, and regulatory sequences for control. This segmentation allows each component to be optimized independently while maintaining overall system functionality and scalability

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent develops universal expression vector systems that can function across multiple host cell types (bacterial, insect, and mammalian cells). The same basic vector architecture and antibody-encoding sequences can be adapted to different expression systems, reducing overall complexity while enabling large-scale production

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentUS11312760B1Expression vector for anti-SARS-CoV-2 neutralizing antibodies

Publication Date: 2022.04.26 NEWSOARA BIOPHARMA CO LTD

AI summary

The present disclosure provides recombinant expression vectors expressing a novel neutralizing antibodies against SARS-COV-2, or the antigen binding fragments thereof. Pharmaceutical composition and kits comprising the same, and the uses thereof are also provided.